These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8188432)

  • 1. Applying benefit-cost analysis to substance use prevention programs.
    Plotnick RD
    Int J Addict; 1994 Feb; 29(3):339-59. PubMed ID: 8188432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financing strategies for drug abuse treatment programs.
    Zarkin GA; Galinis DN; French MT; Fountain DL; Ingram PW; Guyett JA
    J Subst Abuse Treat; 1995; 12(6):385-99. PubMed ID: 8749723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit-cost analysis of drug abuse prevention programs: a macroscopic approach.
    Kim S; Coletti SD; Crutchfield CC; Williams C; Hepler N
    J Drug Educ; 1995; 25(2):111-27. PubMed ID: 7658292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of an educational drug abuse prevention program.
    Mitchel ME; Hu TW; McDonnell NS; Swisher JD
    J Drug Educ; 1984; 14(3):271-92. PubMed ID: 6443126
    [No Abstract]   [Full Text] [Related]  

  • 6. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of inpatient substance abuse treatment.
    Barnett PG; Swindle RW
    Health Serv Res; 1997 Dec; 32(5):615-29. PubMed ID: 9402904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The meaning and utility of drug prices.
    Caulkins J; Reuter P
    Addiction; 1996 Sep; 91(9):1261-4. PubMed ID: 8854356
    [No Abstract]   [Full Text] [Related]  

  • 9. The effectiveness of drug treatment.
    Gerstein DR
    Res Publ Assoc Res Nerv Ment Dis; 1992; 70():253-82. PubMed ID: 1311121
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.
    Miller TR; Zaloshnja E; Spicer RS
    Accid Anal Prev; 2007 May; 39(3):565-73. PubMed ID: 17125723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychotropic drug use and expenditures among medicaid beneficiaries with and without other mental health or substance abuse services.
    Hennessy KD; Green-Hennessy S; Buck JA; Miller K
    J Nerv Ment Dis; 2003 Jul; 191(7):476-8. PubMed ID: 12891096
    [No Abstract]   [Full Text] [Related]  

  • 12. Health promotion in the work-place--beyond an ethnocentric perspective.
    Klingemann HK
    Addiction; 1995 Jul; 90(7):877-81. PubMed ID: 7663310
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic evaluation of a prerelease substance abuse treatment program for repeat criminal offenders.
    French MT; Fang H; Fretz R
    J Subst Abuse Treat; 2010 Jan; 38(1):31-41. PubMed ID: 19631489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An elementary school substance abuse prevention program: teacher and administrator perspectives.
    Flannery DJ; Torquati J
    J Drug Educ; 1993; 23(4):387-97. PubMed ID: 8145115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating primary medical care with addiction treatment: a randomized controlled trial.
    Weisner C; Mertens J; Parthasarathy S; Moore C; Lu Y
    JAMA; 2001 Oct; 286(14):1715-23. PubMed ID: 11594896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of relapse prevention for substance users: treatment settings and health care policy.
    Yamada T; Chen CC; Yamada T
    Adv Health Econ Health Serv Res; 2005; 16():431-50. PubMed ID: 17867251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance abuse treatment services: an introduction.
    Lowman C
    J Ment Health Adm; 1992; 19(1):1-4. PubMed ID: 10171033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.